Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04347239 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
A Phase 2 study, sponsored by CytoDyn.
- Completed
- Registry status
- Phase 2
- Development phase
- 484
- Enrollment target
NCT04347239: Completed Phase 2 study, sponsored by CytoDyn.
NCT04347239 is a Phase 2 study that has completed, run by CytoDyn. The registered enrollment target is 484 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (264% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04347239, a Phase 2 study, has completed, sponsored by CytoDyn.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 484 participants
- Enrollment target
Study Summary
The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
Primary Outcome
Incidence of mortality at day 28
Interventions
- DRUG Placebo
- DRUG Leronlimab (700mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2020-04-16 |
| Est. Completion | 2022-06-15 |
| Phase | Phase 2 |
What the finished NCT04347239 record still lists
NCT04347239 is an interventional study that assigns participants to a tested intervention. The registered 484 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (264% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04347239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04347239 about?
NCT04347239 is a clinical study titled "Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19". The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
What is the current status of trial NCT04347239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 484 participants. The study started on 2020-04-16. Estimated completion is 2022-06-15.
What interventions are being tested in trial NCT04347239?
The interventions under investigation include: Placebo (DRUG), Leronlimab (700mg) (DRUG).
Who is sponsoring clinical trial NCT04347239?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04347239's enrollment target sits among peer trials
484 76th of 2000 higher than 1,925 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
- NCT07124910 · 485 participants · Phase 3
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
- NCT02871726 · 483 participants · NA
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI